Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

Y-MABS THERAPEUTICS, INC.

(YMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Y mAbs Therapeutics : JP Morgan Raises Price Target for Overweight-Rated Y-mAbs Therapeutics to $52 From $57

03/22/2021 | 10:41am EST


ę MT Newswires 2021
All news about Y-MABS THERAPEUTICS, INC.
11/29INSIDER SELL : Y-mAbs Therapeutics
MT
11/24Y-MABS THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statement..
AQ
11/24Y-mAbs Therapeutics, Inc. Announces Executive Changes
CI
11/16Y-mAbs Therapeutics Downgraded, Price Target Cut at JPMorgan
MT
11/16JPMorgan Cuts Y-mAbs Therapeutics to Neutral From Overweight, Price Target to $30 From ..
MT
11/04Y-mAbs Announces Third Quarter Financial Results and Recent Corporate Developments - Fo..
PU
11/04Earnings Flash (YMAB) Y-MABS THERAPEUTICS Posts Q3 Revenue $9M, vs. Street Est of $10.9..
MT
11/04Y-mAbs Announces Third Quarter Financial Results and Recent Corporate Developments
AQ
11/04Y-MABS THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
11/04Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Month..
CI
More news
Analyst Recommendations on Y-MABS THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 66,8 M - -
Net income 2021 -48,8 M - -
Net cash 2021 85,0 M - -
P/E ratio 2021 -15,9x
Yield 2021 -
Capitalization 743 M 743 M -
EV / Sales 2021 9,85x
EV / Sales 2022 3,84x
Nbr of Employees 125
Free-Float 83,8%
Chart Y-MABS THERAPEUTICS, INC.
Duration : Period :
Y-mAbs Therapeutics, Inc. Technical Analysis Chart | YMAB | US9842411095 | MarketScreener
Technical analysis trends Y-MABS THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 17,03 $
Average target price 46,20 $
Spread / Average Target 171%
EPS Revisions
Managers and Directors
Claus Juan M°ller-San Pedro Chief Executive Officer & Director
Thomas Gad Chairman, President & Head-Business Development
Bo Kruse CFO, Secretary. Treasurer & Executive VP
Torben Lund-Hansen Chief Technology Officer & Senior Vice President
Steen Lisby Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
Y-MABS THERAPEUTICS, INC.-65.60%743
GILEAD SCIENCES, INC.21.27%88 622
BIONTECH SE344.70%87 556
REGENERON PHARMACEUTICALS35.46%68 421
WUXI APPTEC CO., LTD.27.38%66 062
VERTEX PHARMACEUTICALS-19.56%48 336